Back to top
more

Paratek Pharmaceuticals, Inc. (PRTK)

(Delayed Data from NSDQ)

$5.36 USD

5.36
183,822

+0.04 (0.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $5.35 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU

by Zacks Equity Research

Vertex (VRTX) receives extension of the marketing application for Orkambi to include use in children with CF who have two copies of the F508del mutation from European Commission.

    Allergan/Paratek's Acne Candidate NDA Filing Accepted by FDA

    by Zacks Equity Research

    Allergan (AGN) and partner Paratek announces that its new drug application for Seysara has been accepted for review by the FDA for moderate to severe acne vulgaris.

      Nabriva's Lefamulin Positive in Pivotal Study, Stock Surges

      by Zacks Equity Research

      Nabriva Therapeutics' (NBRV) lefamulin shows non-inferiority to Avelox in a phase III study on community-acquired bacterial pneumonia patients.

        Paratek Pharmaceuticals, Inc. (PRTK) Catches Eye: Stock Up 27.3%

        by Zacks Equity Research

        Paratek Pharmaceuticals, Inc. (PRTK) was a big mover last session, as the company saw its shares rise over 27% on the day came after news leaked that the company is considering a sale.

          Paratek Antibiotic Candidate's Phase III Data Favorable

          by Zacks Equity Research

          Paratek Pharmaceuticals, Inc. (PRTK) announced positive results from a phase III study (OASIS-2) comparing its antibiotic candidate omadacycline to Pfizer Inc.'s (PFE) Zyvox for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

            Is the Options Market Predicting a Spike in Paratek (PRTK) Stock?

            by Zacks Equity Research

            Investors need to pay close attention to Paratek (PRTK) stock based on the movements in the options market lately.

              Why Paratek Pharmaceuticals (PRTK) Could Be Positioned for a Surge?

              by Zacks Equity Research

              Paratek Pharmaceuticals (PRTK) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.

                Paratek (PRTK) Stock Continues to Rise on Positive Results

                by Zacks Equity Research

                Paratek Pharmaceuticals, Inc.'s (PRTK) shares are up more than 22% since it announced positive results from a phase III study of its lead pipeline candidate

                  Allergan Acne Candidate Meets Endpoints in Phase III Studies

                  by Zacks Equity Research

                  Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline

                    Are Options Traders Betting on a Big Move in Paratek (PRTK) Stock?

                    by Zacks Equity Research

                    Options traders are pricing in a big move for Paratek (PRTK) shares as it has huge implied volatility.

                      Will Paratek Pharmaceuticals (PRTK) Continue to Surge Higher?

                      by Zacks Equity Research

                      As of late, it has definitely been a great time to be an investor in Paratek Pharmaceuticals Inc (PRTK)